跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TRUSELTIQ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TRUSELTIQ
Authorized
STANDARD
TRUSELTIQ
QED Therapeutics, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
8c5a0865c5c79db5
Company
QED Therapeutics, Inc.
Type
Standard
Approval Details
Approval Id
8c5a0865c5c79db5
Drug Approval Canada Name
TRUSELTIQ
Product Name
TRUSELTIQ
Status
Cancelled Pre Market
Status Date
2023-01-23
Din
02520664
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EN03 INFIGRATINIB
Atc Name
l 01 en 03
Aig Number
0163174004
Company Name
QED Therapeutics, Inc.
Company Address
1800 Owens St, 12th Floor, San Francisco, California, United States, 94148
Company Detail Path
/organization/qed-therapeutics-inc
Company Information
Pharmaceutical Company Name
QED Therapeutics, Inc.
Country Name
United States
Province Name
California
City Name
brisbane,california,country_us
Address
8000 Marina Blvd Ste 400
Website
http://www.qedtx.com
Active Ingredients
INFIGRATINIB (INFIGRATINIB PHOSPHATE)
125 MG / DOSE
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
8c5a0865c5c79db5
Type
Standard
Back to Health Canada Approvals